Public Health Surveillance for Adverse Events Following Covid-19 Vaccination in Africa: Rare Adverse Events and Fatal Cases Following COVID-19 Vaccination in Africa

Loading...
Thumbnail Image

Authors

Anjorin, AbdulAzeez
Odetokun, Ismail
Nyandwi, Jean
Elnadi, Hager
Awiagah, Kwame
Eyedo, Joseph
Abioye, Ajibola
Gachara, George
Maisara, Aala
Razouqi, Youssef

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Background: The death toll and economic disaster caused by SARS-CoV-2/ COVID-19 is still on the rise globally and in Africa with a case fatality ratio (CFR), 2.58 from 220,958 deaths out of 8,556,890 cases recorded across the continent as of 14th November 2021. Local, national and international health agencies have advocated multi-pronged public health strategies to limit infections and prevent deaths. The availability of a safe and effective vaccine is critical in the control of a pandemic. Several adverse events have been reported globally for different vaccines including COVID-19 with limited or no data from Africa. Methods: This cross-sectional epidemiological study investigated the adverse events following COVID-19 vaccination in Africans between April- June, 2021 using a structured questionnaire distributed via the web for public health surveillance. Results: Out of the 1200 participants recruited, a total of 80.8% (n = 969) respondents from 35 countries including 22 African countries and 13 countries where Africans live in the diaspora reported different adverse events following COVID-19 vaccination. More than half of the vaccinee were male (53.0%) and frontline healthcare workers (55.7%), respectively. A total of 15.6% (n = 151) reported previous exposure to SARS-CoV-2 while about one-fourth, 24.8% (n = 240) reported different underlying health conditions prior to vaccination. Fatal cases were 5.1% (n = 49) while other significant heterogenous events were reported in three categories: very common, common, and uncommon adverse events including enlarged lymph nodes 2.4% (n = 23), menstrual disorder 0.5% (n = 5), and increased libido 0.2% (n = 2). Conclusions: The study provided useful data for concerned authorities and institutions to prepare plans that will address issues related to COVID-19 vaccines.

Description

Citation

Collections

Endorsement

Review

Supplemented By

Referenced By